Targeted immunotherapies for hematologic malignancies

ARBER Lab

Our focus

Our overall goal is to develop novel targeted immunotherapies for patients with hematologic malignancies. The group develops adoptive T cell therapies with native or engineered receptors and evaluates combinatorial strategies. The objective is to efficiently target tumor cells, mitigate immunosuppressive tumor microenvironment factors, favor tumor-targeted migration and longevity of transferred T cells, control potential toxicities, identify novel personalized targets, and move developments to the clinic.

Our projects

  • To engineer human T cells for targeting hematologic malignancies (chimeric antigen receptors, transgenic T cell receptors, engager molecules etc)

  • To determine if function and persistence of transgenic T cells can be enhanced through (a) reactivating viruses, (b) immune checkpoint blockade or (c) vaccination

  • To develop combinatorial approaches to T cell therapy targeting both the tumor cells and their microenvironment (e.g. engineer tumor-directed migration, resistance to immune inhibitory signals)

  • To engineer signaling switches in T cells that revert tumor-associated immune inhibitory signals.

  • To evaluate 3D culture systems to better model the tumor microenvironment in vitro and apply them to evaluate transgenic T cell function

  • To identify immunogenic mutational tumor neo-antigens in patients with hematologic malignancies and to isolate their neo-antigen specific TCRs for personalized medicine applications.

  • We apply principles from immunology, hematology, cancer and systems biology, use gene transfer and editing technologies to engineer T cells, and collaborate with experts in protein engineering, gene editing, proteomics/ peptidomics, immunomonitoring, bioinformatics, bioengineering, clinical hematology and immuno-oncology. 

TOP ^

KEY PUBLICATIONS

UNIL web teasers general.png

TOP ^

Follow us:  

CONTACT

Lausanne Oncology ARBER lab.png

Caroline ARBER BARTH
Associate Professor
Ludwig adjunct scientist

Laboratory C. Arber

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 21 692 59 53
Email

TOP ^

CONNECT WITH ME

WEB medallions Linked 150 x100-1.png

Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer Research Université de Lausanne Centre Hospitalier Universitaire Vaudois (CHUV)